Trials / Completed
CompletedNCT04481724
Gamma-linolenic Acid Supplementation Study
Effects of Gamma-linolenic Acid Supplementation on Weight Loss Maintenance in the Virta Treatment
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 302 (actual)
- Sponsor
- Virta Health · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Weight regain following weight loss is common. In rodent models of obesity and pilot studies in humans, increasing membrane arachidonic acid content improves fuel partitioning and prevents weight regain. This study aims to understand the effect of gamma-linolenic acid (GLA) supplementation on weight loss maintenance in Virta Health patients.
Detailed description
The primary purpose of this research is to determine if GLA supplementation reduces weight regain over 24 months in Virta Health patients. The secondary purpose is to determine the effect of GLA supplementation on diabetes-related outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | gamma-linolenic acid | 3 capsules per day of GLA for 24 months |
| DIETARY_SUPPLEMENT | placebo | 3 capsules per day of placebo for 24 months |
Timeline
- Start date
- 2020-07-22
- Primary completion
- 2023-02-13
- Completion
- 2023-09-15
- First posted
- 2020-07-22
- Last updated
- 2024-04-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04481724. Inclusion in this directory is not an endorsement.